Magnus Corfitzen, CEO at Ascelia Pharma AB met with Redeye. In this interview, Magnus elaborated on the recent completion of the image reading phase for the SPARKLE Phase 3 re-evaluation study and provided insights into what to expect for the upcoming headline results.